Table 1

Locomotor activity during (Day 19) and after (Day 31) chronic drug infusions
Group Distance traveled
Day 19 Day 31
Taxol-Vehicle 9108.7 ± 390.5 8369.0 ± 161.7
Cremophor-Vehicle 8186.0 ± 355.6 7843.0 ± 275.2
WIN55,212-2 (0.1) 9652.2 ± 396.2 8986.9 ± 1023.7
WIN55,212-2 (0.5) 9100.4 ± 312.7 7679.7 ± 249.0
WIN-2 (0.5) + AM630 (3) 9827.7 ± 333.9* 9407.0 ± 273.4+
WIN-2 (0.5) + AM251 (3) 8739.3 ± 413.4 8699.2 ± 381.1
AM1710 (0.032) 9482.2 ± 419.9 8263.9 ± 423.6
AM1710 (3.2) 8637.4 ± 412.4 7976.1 ± 469.5
AM1710 (3.2) + AM630 (3) 8562.2 ± 364.2 7577.3 ± 499.3
AM1710 (3.2) + AM251 (3) 8378.1 ± 300.7 7269.8 ± 238.3
AM630 (3) 8016.6 ± 482.3 ‒‒‒‒
AM251 (3) 8442.1 ± 420.1 ‒‒‒‒

Data are mean ± s.e.mean (n = 4-14 per group). All groups received paclitaxel (Taxol) with the exception of the cremophor group receiving vehicle via chronic infusion. Statistical comparisons are denoted with line divisions. All divisions within the table were compared against the cremophor- and paclitaxel-vehicle control animals. WIN-2, WIN55,212-2. Doses of drugs indicated parenthetically are in mg/kg/day s.c. *P < 0.05 vs Cremophor-Vehicle, +P < 0.05 vs. Taxol-WIN55,212-2 (0.5 mg/kg/day s.c.) (ANOVA, Tukey Post Hoc).

Rahn et al.

Rahn et al. Molecular Pain 2014 10:27   doi:10.1186/1744-8069-10-27

Open Data